Table 1.

Demographic and clinical data stratified by Aβ positivity

Variable	Total population	Aβ+	Aβ−	P‐value
N	377	151	226
Age (years)	72.1 (5.4)	72.6 (5.0)	71.8 (5.6)	0.10
Sex (female)	50%	44%	54%	0.042
MMSE (0–30 points)	28.3 (1.6)	27.8 (1.6)	28.5 (1.5)	<0.001
APOE ε4‐positive	38%	66%	22%	<0.001
Aβ PET (SUVR)a	0.782 (0.23)	1.023 (0.18)	0.622 (0.05)	<0.001
Hippocampus volume/ICV	0.0045 (0.00069)	0.00425 (0.00062)	0.00468 (0.00068)	<0.001
CSF biomarker (pg/ml)
Aβ42	1,321 (650)	818 (319)	1,657 (596)	<0.001
Aβ40	22,811 (82,293)	29,261 (129,856)	18,501 (5,362)	0.57
Aβ42/Aβ40	0.0717 (0.028)	0.0448 (0.0164)	0.0898 (0.0187)	<0.001
T‐tau	256 (116)	319 (139)	215 (73.0)	<0.001
P‐tau	22.8 (12.4)	30.0 (15.1)	17.9 (6.7)	<0.001
NfL	1,192 (948)	1,399 (1,133)	1,053 (847)	<0.001
Neurogranin	405 (213)	480 (253)	356 (164)	<0.001
YKL‐40	194,090 (63,108)	205,273 (64,958)	186,618 (60,847)	0.003
Plasma biomarker (pg/ml)
Aβ42	31.6 (4.9)	29.9 (4.7)	32.7 (4.7)	<0.001
Aβ40	484 (72)	483 (73)	485 (71)	0.66
Aβ42/Aβ40	0.0657 (0.0082)	0.0622 (0.0078)	0.0680 (0.0077)	<0.001
T‐tau	17.8 (5.3)	18.2 (5.0)	17.6 (5.5)	0.12
P‐tau	2.7 (4.6)	3.4 (3.2)	2.1 (5.3)	<0.001
NfL	22.9 (17.0)	23.9 (11.2)	22.2 (19.9)	0.003
Neurogranin	20,205 (10,655)	19,414 (10,961)	20,735 (10,437)	0.17

Values are in mean (SD) if not otherwise stated. Mann–Whitney was used to compare the Aβ+ and Aβ− groups.

Bold P‐values indicate statistical significance at P < 0.05.

CU, cognitively unimpaired; ICV, intra cranial volume; MCI, mild cognitive impairment; MMSE, Mini‐Mental State Examination; N, number of participants; NfL, neurofilament light chain; P‐tau, phosphorylated‐tau; SD, standard deviation, T‐tau; total‐tau.

^aEarly Aβ accumulating ROI with a composite reference region (see Materials and Methods).